Eltrombopag (Promacta), a Thrombopoetin Receptor Agonist for the Treatment of Thrombocytopenia: Current and Future Considerations
- 1 January 2010
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 17 (1) , 68-74
Abstract
Thrombocytopenia, a decreased platelet count, is a common clinical feature that may be caused by decreased platelet production or accelerated platelet removal. Accelerated platelet removal may result from various immunologic mechanisms, excessive consumption, or sequestration of platelets in the spleen. Thrombocytopenia can range from a transient, isolated finding to a severe, life-threatening condition. Eltrombopag (SB497115) is a novel, orally bioavailable, small-molecule thrombopoetin receptor agonist that induces differentiation and proliferation of megakaryocytes. Preclinical testing on healthy volunteers shows high drug bioavailability and efficacy in raising platelet counts. The 10-day treatment with eltrombopag increased platelet count up to 1.5 times. The drug is usually tolerated well and serious adverse events and discontinuation are rare. There is an unmet need for this agent, and probably eltrombopag is indeed the “drug of choice” for some limited categories of patients; however, its long-term safety profile is unknown. To evaluate the potential drug development, careful analysis of thrombocytopenia morbidity and prevalence of the applicable for treatment with eltrombopag clinical scenarios is highly warranted. Lack of vascular outcome data with regard to potential excessive activity of these next-generation novel platelets may result in increased thrombotic risks and cause worsened cardiovascular and stroke outcomes may be the major obstacle to the success of this promising agent.Keywords
This publication has 15 references indexed in Scilit:
- The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesisHaematologica, 2008
- Emerging treatments for thrombocytopenia: Increasing platelet productionDrug Discovery Today, 2008
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis CNew England Journal of Medicine, 2007
- Thrombopoietin Mimetic Agents in the Management of Immune Thrombocytopenic PurpuraSeminars in Hematology, 2007
- The epidemiology of immune thrombocytopenic purpuraCurrent Opinion in Hematology, 2007
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistBlood, 2007
- Prevalence of immune thrombocytopenia: analyses of administrative dataJournal of Thrombosis and Haemostasis, 2006
- AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPNew England Journal of Medicine, 2006
- Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose DexamethasoneNew England Journal of Medicine, 2003